Literature DB >> 18248772

Genotype-phenotype analysis of the CXCL16 p.Ala181Val polymorphism in inflammatory bowel disease.

Julia Seiderer1, Julia Dambacher, Dorothea Leistner, Cornelia Tillack, Jürgen Glas, Jan-Hendrik Niess, Simone Pfennig, Matthias Jürgens, Bertram Müller-Myhsok, Burkhard Göke, Thomas Ochsenkühn, Peter Lohse, Hans-Christian Reinecker, Stephan Brand.   

Abstract

To identify if genetic determinants of CXCL16 modulate the susceptibility and phenotype of inflammatory bowel diseases (IBD), we analyzed genomic DNA from 574 individuals (365 IBD patients, 209 healthy controls) for the CXCL16 p.Ala181Val polymorphism. In this study, we demonstrate that in Crohn's disease (CD), the CXCL16 p.Ala181Val polymorphism is not a disease susceptibility gene but associated with younger age at disease onset (p=0.016) and higher frequency of ileal involvement (p=0.024; OR 2.17; 95% CI 1.12-4.21) in ValVal carriers compared to a higher frequency of colonic involvement in AlaAla carriers (p=0.009; OR 2.60; CI 1.29-5.25). Carriers of at least one Val allele and one CARD15/NOD2 variant had a higher incidence of a stricturing and penetrating phenotype (p=0.030, OR 4.04, CI 1.27-12.84) and of stenoses (p=0.014; OR 3.97; CI 1.38-11.40) than patients carrying NOD2 variants only, suggesting that this polymorphism contributes to a severe disease phenotype in CD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18248772     DOI: 10.1016/j.clim.2007.11.016

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  8 in total

1.  The presence of fistulas and NOD2 homozygosity strongly predict intestinal stenosis in Crohn's disease independent of the IL23R genotype.

Authors:  Matthias Jürgens; Stephan Brand; Rüdiger P Laubender; Julia Seiderer; Jürgen Glas; Martin Wetzke; Johanna Wagner; Simone Pfennig; Cornelia Tillack; Florian Beigel; Maria Weidinger; Fabian Schnitzler; Martin E Kreis; Burkhard Göke; Peter Lohse; Karin Herrmann; Thomas Ochsenkühn
Journal:  J Gastroenterol       Date:  2010-04-29       Impact factor: 7.527

2.  The gender-specific association of CXCL16 A181V gene polymorphism with susceptibility to multiple sclerosis, and its effects on PBMC mRNA and plasma soluble CXCL16 levels: preliminary findings.

Authors:  Ljiljana Stojković; Aleksandra Stanković; Tamara Djurić; Evica Dinčić; Dragan Alavantić; Maja Zivković
Journal:  J Neurol       Date:  2014-05-23       Impact factor: 4.849

3.  Expression and regulation of the chemokine CXCL16 in Crohn's disease and models of intestinal inflammation.

Authors:  Julia Diegelmann; Julia Seiderer; Jan-Hendrik Niess; Dirk Haller; Burkhard Göke; Hans-Christian Reinecker; Stephan Brand
Journal:  Inflamm Bowel Dis       Date:  2010-11       Impact factor: 5.325

Review 4.  The role of chemokines in intestinal inflammation and cancer.

Authors:  Dingzhi Wang; Raymond N Dubois; Ann Richmond
Journal:  Curr Opin Pharmacol       Date:  2009-09-04       Impact factor: 5.547

5.  NOD2 polymorphism predicts response to treatment in Crohn's disease--first steps to a personalized therapy.

Authors:  Jan Hendrik Niess; Jochen Klaus; Johannes Stephani; Carolin Pflüger; Nadine Degenkolb; Ulrike Spaniol; Benjamin Mayer; Georgia Lahr; Georg B T von Boyen
Journal:  Dig Dis Sci       Date:  2011-12-07       Impact factor: 3.199

6.  The Association of Chemokine Gene Polymorphisms with VKH and Behcet's Disease in a Chinese Han Population.

Authors:  Yang Huang; Hongsong Yu; Qingfeng Cao; Jing Deng; Xinyue Huang; Aize Kijlstra; Peizeng Yang
Journal:  Biomed Res Int       Date:  2017-05-14       Impact factor: 3.411

7.  The Impact of tagSNPs in CXCL16 Gene on the Risk of Myocardial Infarction in a Chinese Han Population.

Authors:  Shun Xu; Jie Cheng; Meng-Yun Cai; Li-Li Liang; Jin-Ming Cen; Xi-Li Yang; Can Chen; Xinguang Liu; Xing-Dong Xiong
Journal:  Dis Markers       Date:  2017-02-14       Impact factor: 3.434

8.  Association of NOD1, CXCL16, STAT6 and TLR4 gene polymorphisms with Malaysian patients with Crohn's disease.

Authors:  Kek Heng Chua; Jin Guan Ng; Ching Ching Ng; Ida Hilmi; Khean Lee Goh; Boon Pin Kee
Journal:  PeerJ       Date:  2016-03-31       Impact factor: 2.984

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.